PTCL Treatment Combination Offers Promising Bridging Strategy to Allogeneic HSCT

Josie Ford, BS, a first-year medical student at the University of Connecticut and a member of the Salvia Jain Lab research team at Massachusetts General Hospital Cancer Center, discussed the combination of duvelisib and romidepsin for relapsed or refractory peripheral T-cell lymphoma and how it serves as an effective bridge to allogeneic hematopoietic stem cell transplant (HSCT).

In her recent study published in Blood Advances, 11 of 17 patients who achieved a complete or partial response were able to bridge to HSCT. This group of patients were younger, had a median of one prior line of therapy, and had a survival rate of 100% compared with 45% in the non-HSCT group.

“This indicates that duvelisib-romidepsin can be a promising treatment for these relapsed or refractory patients who are aiming to bridge to allogeneic stem cell transplant,” Ford explained. “Our data demonstrated the efficacy of the regimen in patients that were even refractory to previous epigenetic modifiers such as azacitidine and romidepsin.”